No Data
Cisen Pharmaceutical (603367.SH) will distribute 0.22 yuan per share for the half-year, with the equity registration date on November 21.
Cisen Pharmaceutical (603367.SH) announced that the company will implement the 2024 semi-annual equity distribution, distributing per share...
Chenxin Pharmaceutical: Report of Chenxin Pharmaceutical Co., Ltd. for the third quarter of 2024
Chenxin Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Cisen Pharmaceutical (603367.SH): The net income for the first three quarters was 0.398 billion yuan, an increase of 1.97% year-on-year.
Great Wisdom October 28th | Cisen Pharmaceutical (603367.SH) released the third quarter report, with revenue of 3 billion yuan in the first three quarters, a 6.47% year-on-year decrease, net income of 0.398 billion yuan, an increase of 1.97% year-on-year, non-net income of 0.363 billion yuan, a 2.49% year-on-year decrease, and basic earnings per share of 0.88 yuan.
Cisen Pharmaceutical, the sales volume of the winning varieties in the group purchase has increased significantly. It is expected that the sales of the large infusion sector will stabilize in the second half of the year. | Live coverage of the earnings co
① At the earnings conference, the director of Cisen Pharmaceutical, Xunxin Xubing, explained the situation of the company's gross margin and revenue decline in the first half of the year; ② Xunxin Xubing stated that the sales volume of four varieties that the company won in the eighth batch of centralized procurement increased significantly compared to the same period last year; ③ The company's chairman, Du Zhenxin, introduced the situation of the company's generic drug and innovative drug research and development.
Chenxin Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
No Data
No Data